摘要
目的探讨重组人干扰素α-2b(IFNα-2b)联合胸腺法新治疗慢性乙型肝炎的临床疗效及不良反应。方法选择94例慢性乙型肝炎患者,随机分成联合组(A组)32例,给予IFNα-2b治疗,第1个月300万IUμd-1,肌内注射,第2、3个月改为隔日300万IU,肌内注射,胸腺法新1.6mg,皮下注射,前4d,1次/d,之后每周2次,连续用6个月。IFNα-2b组(B组)31例,单用IFNα-2b治疗,剂量、方法同A组。胸腺法新组(C组)31例,单用胸腺法新治疗,剂量、方法同A组。3组均3个月为1疗程,治疗2个疗程。结果疗程结束时,3组患者ALT均较治疗前显著下降,差异无统计学意义(P>0.05)。3组患者HBeAg阴转率分别为56.3%、35.3%、32.3%,HBV-DNA阴转率分别为62.5%、38.7%、35.3%,A组的疗效明显高于B、C两组(P<0.05),差异有统计学意义,未见明显不良反应。结论重组人干扰素α-2b联合胸腺法新具有改善肝功能和抑制乙肝病毒复制等功效,两者联合应用可作为治疗慢性乙型肝炎的一种治疗方案,值得在临床推广。
Objective To search out the efficacy and side effects of IFNα-2b combined with Thymalfasin in treating chronic hepatitis B. Methods 94 patients were randomly divided into 3 groups. 32 patients as group A received IFNα-2b 3 million IU μd^-1 ,im for one month, then changed 3 million IU, im for two month and Thymalfasin 1.6 mg, sc, one a dong for 4 dongs, then changed twice a week for 6 months. 31 patients as IFNα-2b group （group B） were given IFNα-2b. 31patients was Thymalfasin group （group C） were given Thymalfasin. Results After the completion of therapy, ALT of 3 groups all reduced. It has no significant difference （P〉O. 05）. Negative rate of HbeAg in 3 groups was 56. 3%, 35. 3% and 32. 3%. Negative rate of HBV-DNA in 3 group was 62. 5%, 38.7% and 35.3%. The efficacy of group A was higher than that of group B and group C （ P 〈 0. 05 ）. Side effects had not been found. Conclusion IFNα-2b combined with Thymalfasin itai can improve liver function. It is can be used in clinic.
出处
《中国实用医药》
2012年第8期50-52,共3页
China Practical Medicine
